PATENT CLAIM ANALYSIS

Application Number: 16144916
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["514", "094000"]

Abstract:
Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as arthritis.

Claim (Index 1):
A method of treating arthritis comprising administering an oral dosage form containing zoledronic acid, in an acid form or a salt form, to a human being in need thereof, wherein the human being receives a total amount of about 100 mg to about 500 mg of the zoledronic acid, wherein the oral dosage form does not contain a bioavailability enhancer, wherein the human being has been fasted for at least 1 hour before the administration of the dosage form and continues to fast for at least 1 hour after the administration of the dosage form, and wherein the human being experiences pain relief that lasts for a duration of at least 48 hours, and the human being receives the dosage form no more often than once daily.

Metadata:
- Claim Count in Document: 45.0
- Percentile: 97.0
- Lexical Diversity: 1.25
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['16002888', '15934785', '15952017', '15989641', '15432777']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.845842555507186
- 35 USC 102 Novelty (BERT): 0.6719097034341481
- Combined Prediction Score: 0.8284492702998822
- Mean Citation Score: 612.5456360000002
- Max Citation Score: 617.901
- Similarity Product: 470.4580262095928

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test